Cannabinoid Encyclopedia

Cannabinoid guide

What is CBN?

CBN is a cannabinoid that can form as THC ages and changes. It is often marketed for sleep, but the human research base is small and its findings are more specific than the marketing claims.

Updated July 2026 35 research sources Human research included

The short answer

CBN, in simple terms

CBN has early human sleep research, but no general sleep or health benefit is established. 1 2 3 4

The approved source set includes small randomized sleep studies, CBN with and without CBD, and rat sleep-architecture research. They measured different products and outcomes, so they cannot be combined into one promise about CBN. 1 2 3 4

What this means: Use this guide to match a question to the study that actually asked it. Falling asleep, waking during the night, sleep quality, next-day effects, safety, pain, skin, and target biology are separate evidence questions. 1 2 3 4

How to read this answer: Use this guide to match a question to the study that actually asked it. Falling asleep, waking during the night, sleep quality, next-day effects, safety, pain, skin, and target biology are separate evidence questions. It includes 14 specific study findings from 4 sources. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about CBN.

Why people look into itSee the main questions before the research details. What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Why people look into CBN

What CBN is commonly talked about for

These cards show the questions most represented in this source set. They are not a list of proven benefits, and the evidence label matters as much as the topic name.

  1. Mostly mechanism-focused

    Skin and inflammatory dermatology

    Skin interest comes from cell, topical, or model-system research involving CBN. That early work does not establish a benefit for a skin condition in people. 6

    See research areas

  2. Mostly mechanism-focused

    Receptor, target, metabolic, and pharmacology mechanisms

    Researchers have looked at CBN in appetite or metabolism-related models. That does not show that it changes appetite, weight, or metabolism for people. 7

    See research areas

  3. Human and early-stage research

    Pain-related outcomes

    People look at CBN for pain because the literature includes pain models, sensory signaling, or related pharmacology. That does not establish pain relief in people. 8

    See research areas

  4. Human research included

    Sleep

    Sleep interest comes from studies that measure one or more sleep outcomes involving CBN. Sleep quality, falling asleep, staying asleep, and next-day effects are separate questions. 9

    See research areas

  5. Human and early-stage research

    Safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns

    Safety research asks how CBN, its dose, route, formulation, and other medications may change risk. The available evidence may not answer the safety question for every product or person. 3

    See research areas

Bottom line: Start with the exact question you care about, then check the study type, product, dose, and outcome before treating a research signal as a real-world effect.

Key takeaways

What to know first

  1. 1

    CBN is a cannabinoid that can form as THC ages and breaks down. 1

  2. 2

    Small randomized studies have tested specific sleep outcomes, not one universal CBN effect. 2

  3. 3

    Animal sleep-architecture findings help map a research question, but they do not establish a human result. 3

Choose your question

Where has CBN been studied?

Start with the exact question you have. CBN studies vary by product, dose, study design, and outcome.

  1. 01Reader question

    Does CBN help sleep?

    Compare sleep quality, awakenings, sleep onset, wake after sleep onset, and next-day measures.

    Explore the evidence
  2. 02Reader question

    What about CBN safety?

    See the human studies, cell-based hazard research, product differences, and evidence gaps.

    Explore the evidence
  3. 03Reader question

    Has CBN been studied for pain?

    Read the limited model and target research without turning it into a human pain claim.

    Explore the evidence
  4. 04Reader question

    What does CBN do biologically?

    Explore receptor and target studies as mechanism research, not proof of a benefit.

    Explore the evidence
  5. 05Reader question

    What about skin or inflammation?

    Open the separate cellular and experimental research route.

    Explore the evidence

Research areas

What has CBN been studied for?

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Human and early-stage research

Safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns

Researchers have examined CBN in connection with Safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns. The studies may differ in compound, formulation, dose, route, population, and outcome. 3

Mostly mechanism-focused

Skin and inflammatory dermatology

Researchers have examined CBN in connection with Skin and inflammatory dermatology. The studies may differ in compound, formulation, dose, route, population, and outcome. 6

Mostly mechanism-focused

Receptor, target, metabolic, and pharmacology mechanisms

Studies connect CBN with Receptor, target, metabolic, and pharmacology mechanisms at the level of receptors, enzymes, signaling, or pharmacology. This helps explain how the biology might work, but it does not prove a health outcome. 7

Human and early-stage research

Pain-related outcomes

Researchers have examined CBN in connection with Pain-related outcomes. The studies may differ in compound, formulation, dose, route, population, and outcome. 8

Human research included

Sleep

Researchers have examined CBN in connection with Sleep. The studies may differ in compound, formulation, dose, route, population, and outcome. 9

Human research included

Overall sleep disturbance

Researchers have examined CBN in connection with Overall sleep disturbance. The studies may differ in compound, formulation, dose, route, population, and outcome. 5

Results extracted so far

What did the studies report?

These summaries appear only when the recorded study outcome is specific enough to reproduce from the linked source. If a source has no result summary here, the result has not been extracted yet; that does not mean the study found no effect.

clinical study in people

Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial

4 recorded findings

PubMed 41698831

  • In a randomized double-blind placebo-controlled crossover trial involving 20 adults with physician-diagnosed insomnia disorder, researchers did not detect a difference in wake after sleep onset following a single oral dose of 30 mg or 300 mg CBN. The recorded comparator was placebo. 2

  • In a randomized double-blind placebo-controlled crossover trial involving 20 adults with physician-diagnosed insomnia disorder, researchers reported shorter sleep onset latency following 300 mg CBN. The recorded comparator was placebo. 2

  • In a randomized double-blind placebo-controlled crossover trial involving 20 adults with physician-diagnosed insomnia disorder, researchers reported higher subjective sleep quality following 300 mg CBN. The recorded comparator was placebo. 2

  • In a randomized double-blind placebo-controlled crossover trial involving 20 adults with physician-diagnosed insomnia disorder, researchers reported more NREM-2 sleep following 300 mg CBN. The recorded comparator was placebo. 2

clinical study in people

A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality

5 recorded findings

PubMed 37796540

  • In a double-blind randomized placebo-controlled study involving adults 18-55 with poor self-rated sleep quality, researchers reported fewer nighttime awakenings following 20 mg CBN over 7 nights. The recorded comparator was placebo. 3

  • In a double-blind randomized placebo-controlled study involving adults 18-55 with poor self-rated sleep quality, researchers reported lower overall sleep disturbance following 20 mg CBN over 7 nights. The recorded comparator was placebo. 3

  • In a double-blind randomized placebo-controlled study involving adults 18-55 with poor self-rated sleep quality, researchers did not detect a difference in sleep onset latency following 20 mg CBN over 7 nights. The recorded comparator was placebo. 3

  • In a double-blind randomized placebo-controlled study involving adults 18-55 with poor self-rated sleep quality, researchers did not detect a difference in wake after sleep onset following 20 mg CBN over 7 nights. The recorded comparator was placebo. 3

  • In a double-blind randomized placebo-controlled study involving adults 18-55 with poor self-rated sleep quality, researchers did not detect a difference in daytime fatigue following 20 mg CBN over 7 nights. The recorded comparator was placebo. 3

rat polysomnography study

A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats

3 recorded findings

PubMed 39528623

  • In a rat polysomnography study, researchers reported more total sleep time. This does not establish the same result in people. 4

  • In a rat polysomnography study, researchers reported more NREM sleep. This does not establish the same result in people. 4

  • In a rat polysomnography study, researchers reported more REM sleep. This does not establish the same result in people. 4

clinical study in people

A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN for Improving Sleep

2 recorded findings

PubMed 39204082

  • In a decentralized randomized double-blind placebo-controlled trial, researchers reported lower overall sleep disturbance following 25 mg, 50 mg, or 100 mg oral CBN formulation. The recorded comparator was placebo and 4 mg melatonin. 5

  • In a decentralized randomized double-blind placebo-controlled trial, researchers did not detect a difference in side effect frequency following 25 mg, 50 mg, or 100 mg oral CBN formulation. The recorded comparator was placebo. 5

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

15 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

11 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

7 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

Another 2 of 35 research sources could not be placed cleanly into those three groups from the recorded study details.

What these studies actually looked at

The research on CBN is not one kind of study. This source set includes 11 narrative or expert reviews, 8 cell or laboratory studies, 6 clinical studies in people, and 3 animal studies. 3

The recorded populations or models include people or patients (15 sources), cells or tissue models (4 sources), and animal models (2 sources). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns (9 sources), skin, dermatology, inflammatory, or immune-modulation outcomes (9 sources), and receptor, target, metabolic, or pharmacology mechanisms (8 sources). Closely related outcome names can still describe different measurements. 5

Some source records specify doses including 20 mg CBN (1 source), 25 mg, 50 mg, or 100 mg oral CBN formulation (1 source), and 300 mg CBN (1 source). These are descriptions of what researchers tested, not personal dosing instructions. 6

The CBN source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 7

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

narrative or expert review

Cannabinol and Sleep: Separating Fact from Fiction

On this page, this source examines an association between CBN and sleep-promoting claims in the pre-2021 evidence base. 1

Study type
narrative or expert review
Evidence stage
evidence still limited

clinical study in people

Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial

On this page, this source examines CBN and wake after sleep onset, CBN and sleep onset latency, and CBN and subjective sleep quality and other related questions. 2

Study type
clinical study in people
Population or model
20 adults with physician-diagnosed insomnia disorder and people or patients
Outcome focus
polysomnography wake after sleep onset and sleep onset latency and other recorded details
Dose recorded
single oral dose of 30 mg or 300 mg CBN and 300 mg CBN and other recorded details
Evidence stage
human research

clinical study in people

A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality

On this page, this source examines CBN and nighttime awakenings, CBN and sleep onset latency, wake after sleep onset, or daytime fatigue, and CBN and overall sleep disturbance and other related questions. 3

Study type
clinical study in people
Population or model
adults 18-55 with poor self-rated sleep quality and people or patients
Outcome focus
number of awakenings and sleep onset latency, wake after sleep onset, or daytime fatigue and other recorded details
Dose recorded
20 mg CBN
Evidence stage
human research

rat polysomnography study

A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats

On this page, this source examines CBN and total sleep time, CBN and nREM sleep, and CBN and rEM sleep and other related questions. 4

Study type
rat polysomnography study and mechanism-focused study
Population or model
rats
Outcome focus
total sleep time and nREM sleep and other recorded details
Evidence stage
preclinical research and mechanism-focused research

clinical study in people

A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN for Improving Sleep

On this page, this source examines CBN and overall sleep disturbance and CBN and side effect frequency. 5

Study type
clinical study in people
Population or model
people or patients
Outcome focus
pROMIS Sleep Disturbance 8A and side effect frequency
Dose recorded
25 mg, 50 mg, or 100 mg oral CBN formulation
Evidence stage
human research

Safety and limits

What should readers keep in mind?

Research on CBN should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 3

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

What is CBN?

CBN is a cannabinoid found in cannabis. It can form as THC changes over time, and it has a different research profile from CBD or THC. 7

Is CBN proven to help sleep?

No general sleep benefit is established. Small human studies report specific findings, including some changes in nighttime awakenings or sleep disturbance, but results differ by endpoint and product. 8

Is CBN with CBD the same as CBN alone?

No. A CBN and CBD combination tests more than one cannabinoid, so its findings cannot automatically be credited to CBN alone. 9

What else has CBN been studied for?

The current evidence set also includes safety, biological-target, pain, skin, and inflammation questions. Most of that research is early-stage. 10

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Cannabinol and Sleep: Separating Fact from Fiction narrative or expert review; evidence still limited PubMed 34468204 DOI 10.1089/can.2021.0006
  2. 2
    Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial clinical study in people; human research PubMed 41698831 DOI 10.1111/jsr.70284
  3. 3
    A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality clinical study in people; human research PubMed 37796540 DOI 10.1037/pha0000682
  4. 4
    A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats rat polysomnography study; mechanism-focused study; preclinical research; mechanism-focused research PubMed 39528623 DOI 10.1038/s41386-024-02018-7
  5. 5
    A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN for Improving Sleep clinical study in people; human research PubMed 39204082 DOI 10.3390/ph17080977
  6. 6
    Anti-inflammatory and analgesic potential of minor cannabinoids in vivo. animal study; mechanism-focused research PubMed 41680865 DOI 10.1186/s42238-025-00384-7
  7. 7
    Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms. systematic review or meta-analysis; evidence still limited PubMed 40967679 DOI 10.1016/bs.pbr.2025.07.006
  8. 8
    Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception. mechanism-focused research PubMed 19679411 DOI 10.1016/j.drugalcdep.2009.06.009
  9. 9
    Using Cannabis and CBD to Sleep: An Updated Review. narrative or expert review; evidence still limited PubMed 39612156 DOI 10.1007/s11920-024-01564-7
  10. 10
    Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder ('CUPID' study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial. clinical study in people; evidence still limited PubMed 37612115 DOI 10.1136/bmjopen-2022-071148
  11. 11
    Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial. clinical study in people; human research PubMed 39980821 DOI 10.1002/hsr2.70481
  12. 12
    Medical cannabis for treatment of insomnia in adults: A systematic review and meta-analysis. human research PubMed 42207928 DOI 10.1097/jxx.0000000000001289
See all 35 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Cannabinol and Sleep: Separating Fact from Fiction narrative or expert review; evidence still limited / 1 linked research note PubMed 34468204
  2. A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality clinical study in people; human research / 7 linked research notes PubMed 37796540
  3. A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN for Improving Sleep clinical study in people; human research / 2 linked research notes PubMed 39204082
  4. Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial clinical study in people; human research / 7 linked research notes PubMed 41698831
  5. A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats rat polysomnography study; mechanism-focused study; preclinical research; mechanism-focused research / 4 linked research notes PubMed 39528623
  6. Using Cannabis and CBD to Sleep: An Updated Review. narrative or expert review; evidence still limited / 1 linked research note PubMed 39612156
  7. Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder ('CUPID' study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial. clinical study in people; evidence still limited / 1 linked research note PubMed 37612115
  8. Cannabinoids, Insomnia, and Other Sleep Disorders. narrative or expert review; evidence still limited / 1 linked research note PubMed 35537535
  9. Medical cannabis for treatment of insomnia in adults: A systematic review and meta-analysis. human research / 1 linked research note PubMed 42207928
  10. Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial. clinical study in people; human research / 2 linked research notes PubMed 39980821
  11. Comparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 39004335
  12. The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. clinical study in people; human research / 1 linked research note PubMed 37162192
  13. Examining the hepatotoxic potential of cannabidiol, cannabidiol-containing hemp extract, and cannabinol at consumer-relevant exposure concentrations in primary human hepatocytes. cell or laboratory study; evidence still limited / 1 linked research note PubMed 38924151
  14. [Cannabis: Effects in the Central Nervous System. Therapeutic, societal and legal consequences]. narrative or expert review; evidence still limited / 1 linked research note PubMed 27428345
  15. Review of NIOSH Cannabis-Related Health Hazard Evaluations and Research. evidence still limited / 1 linked research note PubMed 32053725
  16. Evaluation of the anti-inflammatory effects of selected cannabinoids and terpenes from Cannabis Sativa employing human primary leukocytes. cell or laboratory study; evidence still limited; mechanism-focused research / 2 linked research notes PubMed 36228902
  17. Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 40967679
  18. Cannabinoid receptor 2 (Cb2r) mediates cannabinol (CBN) induced developmental defects in zebrafish. cell or laboratory study; mechanism-focused research; evidence still limited / 2 linked research notes PubMed 36424484
  19. Pharmacological actions of cannabinoids. narrative or expert review; evidence still limited / 1 linked research note PubMed 16596770
  20. Molecular Pharmacology of Phytocannabinoids. narrative or expert review; evidence still limited / 1 linked research note PubMed 28120231
  21. The peripheral cannabinoid receptor, Cb2, in retrovirally-induced leukemic transformation and normal hematopoiesis. narrative or expert review; evidence still limited / 1 linked research note PubMed 10036999
  22. Affinity-Based Protein Profiling Reveals IDH2 as a Mitochondrial Target of Cannabinol in Receptor-Independent Neuroprotection. mechanism-focused research / 1 linked research note PubMed 40388656
  23. Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use. narrative or expert review; evidence still limited / 2 linked research notes PubMed 38673788
  24. Modulation of type 1 cannabinoid receptor activity by cannabinoid by-products from Cannabis sativa and non-cannabis phytomolecules. animal study; mechanism-focused research / 1 linked research note PubMed 36091813
  25. Anti-inflammatory and analgesic potential of minor cannabinoids in vivo. animal study; mechanism-focused research / 1 linked research note PubMed 41680865
  26. Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 37764262
  27. Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 39275884
  28. Cannabinoids, inflammation, and fibrosis. narrative or expert review; evidence still limited / 2 linked research notes PubMed 27435265
  29. Phytocannabinoids as anti-inflammatory agents: Synergistic effects when combined with Cannabis sativa L. matrices. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 41478536
  30. Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosis. animal study; mechanism-focused research / 1 linked research note PubMed 40580876
  31. Distinct Interactions of Cannabinol and Its Cytochrome P450-Generated Metabolites with Receptors and Sensory Neurons. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 40568800
  32. Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception. mechanism-focused research / 1 linked research note PubMed 19679411
  33. [Marijuana--2000]. narrative or expert review; evidence still limited / 1 linked research note PubMed 11367861
  34. Nav1.8, an analgesic target for nonpsychotomimetic phytocannabinoids. human research / 1 linked research note PubMed 39835903
  35. Cannabis: Chemistry, extraction and therapeutic applications. narrative or expert review; evidence still limited / 1 linked research note PubMed 34838836